Generate a tailored SOP for Dr. Melinda Telli. Improve your application with a focused, well-structured draft.
Melinda L. Telli, M.D. is a Professor in the Department of Medicine at Stanford University, specializing in Medical Oncology. She serves as the Director of the Breast Cancer Program and Associate Director of Clinical Research at the Stanford Cancer Institute. Her research primarily focuses on developing novel therapies for triple-negative hereditary breast cancer and validating biomarkers to identify patients who may benefit from DNA repair defect-targeted therapies. Dr. Telli’s involvement in clinical development of PARP inhibitors has led to significant insights in breast cancer treatment, especially concerning BRCA1 and BRCA2 mutation-associated cancers. An alumna of the University of Pennsylvania and George Washington University, she completed her training at Stanford University. Active in professional societies, Dr. Telli has served on numerous committees for the American Society of Clinical Oncology and is a member of the Editorial Board for the Journal of Clinical Oncology. She has received multiple awards for her contributions to the field, showcasing her commitment to advancing cancer research and patient care.
Stanford Cancer Institute • Stanford, California
Oversees the Breast Cancer Program's research initiatives and clinical trials.
Stanford Cancer Institute • Stanford, California
Leads clinical research efforts related to breast cancer.
Stanford University School of Medicine • Stanford, California
Contributes to the administration and strategic planning of oncology.
The Computer Science department emphasizes research potential. GRE General is currently optional but recommended for some tracks.